5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.45▼ | 6.44▼ | 6.39▲ | 6.44▼ | 6.96▼ |
MA10 | 6.46▼ | 6.38▲ | 6.38▲ | 6.50▼ | 7.43▼ |
MA20 | 6.44▼ | 6.37▲ | 6.41▲ | 7.04▼ | 8.32▼ |
MA50 | 6.40▲ | 6.47▼ | 6.34▲ | 7.69▼ | 7.36▼ |
MA100 | 6.43▼ | 6.41▲ | 6.74▼ | 8.53▼ | 7.68▼ |
MA200 | 6.40▲ | 6.86▼ | 7.36▼ | 7.54▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.006▼ | 0.016▲ | 0.007▲ | -0.025▼ | -0.358▼ |
RSI | 48.834▼ | 50.368▲ | 50.804▲ | 39.176▼ | 41.092▼ |
STOCH | 19.886▼ | 72.296 | 58.621 | 32.762 | 14.378▼ |
WILL %R | -100.000▼ | -38.776 | -30.159 | -68.817 | -89.057▼ |
CCI | -117.662▼ | 56.646 | 85.067 | -57.291 | -124.983▼ |
CDL | $NVCT Doji Candlestick Pattern Detected | Set Alert |
Tuesday, August 12, 2025 02:24 AM
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat ...
|
Monday, August 11, 2025 01:42 PM
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in ...
|
Friday, August 08, 2025 04:16 PM
Net loss per share (GAAP) was $ (0.30), reflecting a higher loss than prior year. Cash and cash equivalents (GAAP) were $26.8 million, with a pro forma total of about $39 million as of June 30, 2025, ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 6.45 | 6.525 | 6.23 | 6.43 | 51,300 |
14/08/25 | 6.32 | 6.49 | 6.20 | 6.43 | 60,751 |
13/08/25 | 6.90 | 6.99 | 6.34 | 6.37 | 136,800 |
12/08/25 | 6.15 | 6.82 | 6.15 | 6.82 | 190,211 |
11/08/25 | 6.02 | 6.36 | 5.97 | 6.13 | 123,465 |
08/08/25 | 6.15 | 6.505 | 5.85 | 6.00 | 177,213 |
07/08/25 | 6.62 | 6.62 | 6.05 | 6.17 | 277,100 |
06/08/25 | 6.80 | 7.01 | 6.42 | 6.46 | 170,200 |
05/08/25 | 7.16 | 7.37 | 6.81 | 6.90 | 288,300 |
04/08/25 | 6.80 | 7.38 | 6.7713 | 7.29 | 101,861 |
|
|
||||
|
|
||||
|
|